TY - JOUR T1 - Quantifying SARS-CoV-2 spread in Switzerland based on genomic sequencing data JF - medRxiv DO - 10.1101/2020.10.14.20212621 SP - 2020.10.14.20212621 AU - Sarah Nadeau AU - Christiane Beckmann AU - Ivan Topolsky AU - Timothy Vaughan AU - Emma Hodcroft AU - Tobias Schär AU - Ina Nissen AU - Natascha Santacroce AU - Elodie Burcklen AU - Pedro Ferreira AU - Kim Philipp Jablonski AU - Susana Posada-Céspedes AU - Vincenzo Capece AU - Sophie Seidel AU - Noemi Santamaria de Souza AU - Julia M. Martinez-Gomez AU - Phil Cheng AU - Philipp P. Bosshard AU - Mitchell P. Levesque AU - Verena Kufner AU - Stefan Schmutz AU - Maryam Zaheri AU - Michael Huber AU - Alexandra Trkola AU - Samuel Cordey AU - Florian Laubscher AU - Ana Rita Gonçalves AU - Karoline Leuzinger AU - Madlen Stange AU - Alfredo Mari AU - Tim Roloff AU - Helena Seth-Smith AU - Hans H. Hirsch AU - Adrian Egli AU - Maurice Redondo AU - Olivier Kobel AU - Christoph Noppen AU - Niko Beerenwinkel AU - Richard A. Neher AU - Christian Beisel AU - Tanja Stadler Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/30/2020.10.14.20212621.abstract N2 - Pathogen genomes provide insights into their evolution and epidemic spread. We sequenced 1,439 SARS-CoV-2 genomes from Switzerland, representing 3-7% of all confirmed cases per week. Using these data, we demonstrate that no one lineage became dominant, pointing against evolution towards general lower virulence. On an epidemiological level, we report no evidence of cryptic transmission before the first confirmed case. We find many early viral introductions from Germany, France, and Italy and many recent introductions from Germany and France. Over the summer, we quantify the number of non-traceable infections stemming from introductions, quantify the effective reproductive number, and estimate the degree of undersampling. Our framework can be applied to quantify evolution and epidemiology in other locations or for other pathogens based on genomic data.One Sentence Summary We quantify SARS-CoV-2 spread in Switzerland based on genome sequences from our nation-wide sequencing effort.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSN and TS are supported by the Swiss National Science Foundation (grant number 31CA30_196267).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data used is available on https://www.gisaid.org/. ER -